Stoke Therapeutics, Inc. (STOK) stock
STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30173% above fair value
$26.41−0.22 (-0.83%)
Close on Nov 17, 2026Market cap $1.70BP/E –Yield –
Stoke Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Stoke Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$177.99M, down 389.0% year over year. For fiscal 2025 it was $45.59M. The highest annual figure on record is $45.59M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.59M | – |
| FY2024 | Dec 31, 2024 | -$86.85M | – |
| FY2023 | Dec 31, 2023 | -$81.07M | – |
| FY2022 | Dec 31, 2022 | -$31.87M | – |
| FY2021 | Dec 31, 2021 | -$66.91M | – |
| FY2020 | Dec 31, 2020 | -$42.22M | – |
| FY2019 | Dec 31, 2019 | -$31.06M | – |
| FY2018 | Dec 31, 2018 | -$10.96M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$56.59M | – |
| Q1 FY2026 | Mar 31, 2026 | -$60.58M | -146.0% |
| Q4 FY2025 | Dec 31, 2025 | -$30.45M | – |
| Q3 FY2025 | Sep 30, 2025 | -$30.37M | – |
| Q2 FY2025 | Jun 30, 2025 | -$25.42M | – |
| Q1 FY2025 | Mar 31, 2025 | $131.83M | – |
| Q4 FY2024 | Dec 31, 2024 | -$23.19M | – |
| Q3 FY2024 | Sep 30, 2024 | -$21.62M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.48M | – |
| Q1 FY2024 | Mar 31, 2024 | -$24.57M | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.65M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.26M | – |
| Q2 FY2023 | Jun 30, 2023 | -$21.80M | – |
| Q1 FY2023 | Mar 31, 2023 | -$21.36M | -165.7% |
| Q4 FY2022 | Dec 31, 2022 | -$22.37M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.06M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.93M | – |
| Q1 FY2022 | Mar 31, 2022 | $32.49M | – |
| Q4 FY2021 | Dec 31, 2021 | -$16.26M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.68M | – |
| Q2 FY2021 | Jun 30, 2021 | -$15.83M | – |
| Q1 FY2021 | Mar 31, 2021 | -$20.14M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.93M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.87M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.65M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.77M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.20M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.05M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.27M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.53M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.52M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.04M | – |
See a number that looks wrong?